UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

BRAF mutations and BRAF mutation functional class have no negative impact on the clinical outcome of advanced NSCLC and associate with susceptibility to immunotherapy

European journal of cancer (1990), 2021-05, Vol.149, p.211-221

2021

Volltextzugriff (PDF)

The multifaceted anti-cancer effects of BRAF-inhibitors

Oncotarget, 2019-11, Vol.10 (61), p.6623-6640

2019

Volltextzugriff (PDF)

Clinicogenomic Features and Targetable Mutations in NSCLCs Harboring BRAF Non-V600E Mutations: A Multi-Institutional Genomic Screening Study (LC-SCRUM-Asia)

Journal of thoracic oncology, 2023-11, Vol.18 (11), p.1538-1549

2023

Volltextzugriff (PDF)

Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600–mutant melanoma

European journal of cancer (1990), 2020-02, Vol.126, p.33-44

2020

Volltextzugriff (PDF)

Clinical Development of BRAF plus MEK Inhibitor Combinations

Trends in Cancer, 2020-09, Vol.6 (9), p.797-810

2020

Volltextzugriff (PDF)

Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma

The American journal of surgical pathology, 2013-01, Vol.37 (1), p.61-65

2013

Volltextzugriff (PDF)

Gender-based differences in the efficacy of anti-EGFR/BRAF/MEK targeted therapy in patients with BRAF-mutated metastatic colorectal cancer

Seminars in oncology, 2024-10

2024

Volltextzugriff (PDF)

BRAF mutations and concurrent alterations in patients with soft tissue sarcoma

Genes chromosomes & cancer, 2023-11, Vol.62 (11), p.648-654

2023

Volltextzugriff (PDF)

FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non‐Small Cell Lung Cancers Harboring BRAF V600E Mutations

The oncologist (Dayton, Ohio), 2018-06, Vol.23 (6), p.740-745

2018

Volltextzugriff (PDF)

First-line encorafenib plus binimetinib and pembrolizumab for advanced BRAF V600-mutant melanoma: Safety lead-in results from the randomized phase III STARBOARD study

European journal of cancer (1990), 2024-12, Vol.213, p.115070, Article 115070

2024

Volltextzugriff (PDF)

Interplay among BRAF, p16, p53, and MIB1 in pediatric low-grade gliomas

Neuro-oncology (Charlottesville, Va.), 2012-06, Vol.14 (6), p.777-789

2012

Volltextzugriff (PDF)

Inmunoterapia vs. terapia diana en el paciente con melanoma avanzado y mutación BRAF V600, ¿por cuál comenzar?

Actas dermo-sifiliográficas, 2024-01, Vol.115 (1), p.48-55

2024

Volltextzugriff (PDF)

BRAFV600E promotes anchorage-independent growth but inhibits anchorage-dependent growth in hTERT/Cdk4-Immortalized normal human bronchial epithelial cells

Experimental cell research, 2024-06, Vol.439 (1), p.114057, Article 114057

2024

Volltextzugriff (PDF)

BRAF promotes anchorage-independent growth but inhibits anchorage-dependent growth in hTERT/Cdk4-Immortalized normal human bronchial epithelial cells

Experimental cell research, 2024-06, Vol.439 (1), p.114057, Article 114057

2024

Volltextzugriff (PDF)

FOXP3 (rs 3761548) and BRAF (V600E ) gene polymorphism among Egyptians with hepatocellular carcinoma

Egyptian Journal of Basic and Applied Sciences, 2024-12, Vol.11 (1), p.11-24

2024

Volltextzugriff (PDF)

Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p.V600E and non-p.V600E BRAF mutations

BMC cancer, 2014-01, Vol.14 (1), p.13-13

2014

Volltextzugriff (PDF)

AEBP1 upregulation confers acquired resistance to BRAF (V600E) inhibition in melanoma

Cell death & disease, 2013-11, Vol.4 (11), p.e914-e914

2013

Volltextzugriff (PDF)

Phenotype switching in melanoma: implications for progression and therapy

Frontiers in oncology, 2015-02, Vol.5, p.31-31

2015

Volltextzugriff (PDF)

Anti-PD-1/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy

Cancer cell, 2021-10, Vol.39 (10), p.1375-1387.e6

2021

Volltextzugriff (PDF)

Differential expression of Tim3 protein in colorectal cancer associated with MSI and Braf mutation

Histology and histopathology, 2022-05, Vol.37 (5), p.441-448

2022

Volltextzugriff (PDF)

A validated prognostic classifier for BRAF-mutated metastatic colorectal cancer: the ‘BRAF BeCool’ study

European journal of cancer (1990), 2019-09, Vol.118, p.121-130

2019

Volltextzugriff (PDF)

Thyroid carcinoma: molecular pathways and therapeutic targets

Modern pathology, 2008-05, Vol.21, p.S37-S43

Nikiforov, Yuri E

2008

Volltextzugriff (PDF)

Management of BRAF Gene Alterations in Metastatic Colorectal Cancer: From Current Therapeutic Strategies to Future Perspectives

Frontiers in oncology, 2021-03, Vol.11, p.602194-602194

2021

Volltextzugriff (PDF)

Detection of the BRAF V600E mutation in colon carcinoma: critical evaluation of the imunohistochemical approach

The American journal of surgical pathology, 2014-09, Vol.38 (9), p.1235-1241

2014

Volltextzugriff (PDF)

European expert panel consensus on the clinical management of BRAF-mutant metastatic colorectal cancer

Cancer treatment reviews, 2023-04, Vol.115, p.102541, Article 102541

2023

Volltextzugriff (PDF)

1 – 25 von 7.311

Suche als RSS-Feed

Aktive Filter

SpracheJapanisch

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(6.417)
Mit Volltextzugriff
(6.147)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

8 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(5.826)
Life Sciences & Biomedicine
(5.744)
Braf
(3.970)
Humans
(3.843)
Mutation
(3.138)
Oncology
(2.887)
Proto-Oncogene Proteins B-Raf - Genetics
(2.568)
Melanoma
(2.015)
Female
(1.823)
Male
(1.753)
Middle Aged
(1.444)
Tumors
(1.363)
Aged
(1.189)
Adult
(1.185)
Pathology
(1.143)
Metastasis
(891)
Kinases
(878)
Colorectal Cancer
(872)
Braf Mutation
(816)
Prognosis
(809)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

MEDLINE
(3.906)
EZB Electronic Journals Library
(3.558)
IngentaConnect
(3.446)
Journals@Ovid Ovid Full Text
(2.482)
IngentaConnect Journals
(1.859)
Elsevier ScienceDirect Journals Complete
(1.139)
SpringerLink Journals
(1.033)
Wiley Online Library - AutoHoldings Journals
(1.012)
Wiley Online Library Full Collection 2018
(803)
Single Journals
(660)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(657)
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(645)
Taylor & Francis Journals
(500)
Taylor & Francis
(377)
Taylor & Francis:Master (3349 titles)
(264)
Ebook Central Perpetual and DDA
(229)
eBooks on EBSCOhost
(217)
Nexis Uni
(149)
SAGE Journals Online
(145)
Nature Journals Online
(131)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Cancers
(181)
Frontiers In Oncology
(149)
Oncotarget
(147)
Melanoma Research
(113)
International Journal Of Molecular Sciences
(101)
Annales De Dermatologie Et De Vénéréologie
(100)
European Journal Of Cancer
(92)
Human Pathology
(91)
Bmc Cancer
(87)
The American Journal Of Surgical Pathology
(80)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

BRAF mutations and BRAF mutation functional class have no negative impact on the clinical outcome of advanced NSCLC and associate with susceptibility to immunotherapy

The multifaceted anti-cancer effects of BRAF-inhibitors

Clinicogenomic Features and Targetable Mutations in NSCLCs Harboring BRAF Non-V600E Mutations: A Multi-Institutional Genomic Screening Study (LC-SCRUM-Asia)

Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600–mutant melanoma

Clinical Development of BRAF plus MEK Inhibitor Combinations

Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma

Gender-based differences in the efficacy of anti-EGFR/BRAF/MEK targeted therapy in patients with BRAF-mutated metastatic colorectal cancer

BRAF mutations and concurrent alterations in patients with soft tissue sarcoma

FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non‐Small Cell Lung Cancers Harboring BRAF V600E Mutations

First-line encorafenib plus binimetinib and pembrolizumab for advanced BRAF V600-mutant melanoma: Safety lead-in results from the randomized phase III STARBOARD study

Interplay among BRAF, p16, p53, and MIB1 in pediatric low-grade gliomas

Inmunoterapia vs. terapia diana en el paciente con melanoma avanzado y mutación BRAF V600, ¿por cuál comenzar?

BRAFV600E promotes anchorage-independent growth but inhibits anchorage-dependent growth in hTERT/Cdk4-Immortalized normal human bronchial epithelial cells

BRAF promotes anchorage-independent growth but inhibits anchorage-dependent growth in hTERT/Cdk4-Immortalized normal human bronchial epithelial cells

FOXP3 (rs 3761548) and BRAF (V600E ) gene polymorphism among Egyptians with hepatocellular carcinoma

Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p.V600E and non-p.V600E BRAF mutations

AEBP1 upregulation confers acquired resistance to BRAF (V600E) inhibition in melanoma

Phenotype switching in melanoma: implications for progression and therapy

Anti-PD-1/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy

Differential expression of Tim3 protein in colorectal cancer associated with MSI and Braf mutation

A validated prognostic classifier for BRAF-mutated metastatic colorectal cancer: the ‘BRAF BeCool’ study

Thyroid carcinoma: molecular pathways and therapeutic targets

Management of BRAF Gene Alterations in Metastatic Colorectal Cancer: From Current Therapeutic Strategies to Future Perspectives

Detection of the BRAF V600E mutation in colon carcinoma: critical evaluation of the imunohistochemical approach

European expert panel consensus on the clinical management of BRAF-mutant metastatic colorectal cancer

Aktive Filter

Suchergebnisse filtern